<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333874</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2288</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC medical research methodology</Title><ISOAbbreviation>BMC Med Res Methodol</ISOAbbreviation></Journal><ArticleTitle>A Bayesian multivariate hierarchical model for developing a treatment benefit index using mixed types of outcomes.</ArticleTitle><Pagination><StartPage>218</StartPage><MedlinePgn>218</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">218</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12874-024-02333-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Precision medicine has led to the development of targeted treatment strategies tailored to individual patients based on their characteristics and disease manifestations. Although precision medicine often focuses on a single health outcome for individualized treatment decision rules (ITRs), relying only on a single outcome rather than all available outcomes information leads to suboptimal data usage when developing optimal ITRs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To address this limitation, we propose a Bayesian multivariate hierarchical model that leverages the wealth of correlated health outcomes collected in clinical trials. The approach jointly models mixed types of correlated outcomes, facilitating the "borrowing of information" across the multivariate outcomes, and results in a more accurate estimation of heterogeneous treatment effects compared to using single regression models for each outcome. We develop a treatment benefit index, which quantifies the relative benefit of the experimental treatment over the control treatment, based on the proposed multivariate outcome model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We demonstrate the strengths of the proposed approach through extensive simulations and an application to an international Coronavirus Disease 2019 (COVID-19) treatment trial. Simulation results indicate that the proposed method reduces the occurrence of erroneous treatment decisions compared to a single regression model for a single health outcome. Additionally, the sensitivity analyses demonstrate the robustness of the model across various study scenarios. Application of the method to the COVID-19 trial exhibits improvements in estimating the individual-level treatment efficacy (indicated by narrower credible intervals for odds ratios) and optimal ITRs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The study jointly models mixed types of outcomes in the context of developing ITRs. By considering multiple health outcomes, the proposed approach can advance the development of more effective and reliable personalized treatment.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Danni</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine, 180 Madison Avenue, New York, 10016, New York, USA. dw2625@nyu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Boston, 02115, MA, USA. dw2625@nyu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldfeld</LastName><ForeName>Keith S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine, 180 Madison Avenue, New York, 10016, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petkova</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine, 180 Madison Avenue, New York, 10016, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyung G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine, 180 Madison Avenue, New York, 10016, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR001445</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Med Res Methodol</MedlineTA><NlmUniqueID>100968545</NlmUniqueID><ISSNLinking>1471-2288</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Jan 07:2023.11.17.23298711. doi: 10.1101/2023.11.17.23298711</RefSource><PMID Version="1">38014277</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="Y">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bayesian multivariate hierarchical model</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Individualized treatment decision rule</Keyword><Keyword MajorTopicYN="N">Precision medicine</Keyword><Keyword MajorTopicYN="N">Treatment benefit index model</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333874</ArticleId><ArticleId IdType="pmc">PMC11437666</ArticleId><ArticleId IdType="doi">10.1186/s12874-024-02333-z</ArticleId><ArticleId IdType="pii">10.1186/s12874-024-02333-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Qian M, Murphy SA. Performance guarantees for individualized treatment rules. Ann Stat. 2011;39(2):1180–210. 10.1214/10-AOS864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3110016</ArticleId><ArticleId IdType="pubmed">21666835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Zhang HH, Zeng D. Variable selection for optimal treatment decision. Stat Methods Med Res. 2013;22(5):493–504. 10.1177/0962280211428383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3303960</ArticleId><ArticleId IdType="pubmed">22116341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zeng D, Rush AJ, Kosorok MR. Estimating individualized treatment rules using outcome weighted learning. J Am Stat Assoc. 2012;107:1106–18. 10.1080/01621459.2012.695674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636816</ArticleId><ArticleId IdType="pubmed">23630406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L, Alizadeh AA, Gentles AJ, Tibshirani R. A simple method for estimating interactions between a treatment and a large number of covariates. J Am Stat Assoc. 2014;109(508):1517–32. 10.1080/01621459.2014.951443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4338439</ArticleId><ArticleId IdType="pubmed">25729117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zheng D, Laber EB, Kosorok MR. New statistical learning methods for estimating optimal dynamic treatment regimes. J Am Stat Assoc. 2015;110:583–98. 10.1080/01621459.2014.937488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517946</ArticleId><ArticleId IdType="pubmed">26236062</ArticleId></ArticleIdList></Reference><Reference><Citation>Song R, Kosorok M, Zeng D, Zhao Y, Laber EB, Yuan M. On sparse representation for optimal individualized treatment selection with penalized outcome weighted learning. Stat. 2015;4:59–68. 10.1002/sta4.78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394905</ArticleId><ArticleId IdType="pubmed">25883393</ArticleId></ArticleIdList></Reference><Reference><Citation>Laber EB, Zhao Y. Tree-based methods for individualized treatment regimes. Biometrika. 2015;102:501–14. 10.1093/biomet/asv028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755313</ArticleId><ArticleId IdType="pubmed">26893526</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C, Song R, Lu W. Robust learning for optimal treatment decision with np-dimensionality. Electron J Stat. 2016;10:2894–921. 10.1214/16-EJS1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5544015</ArticleId><ArticleId IdType="pubmed">28781717</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkova E, Tarpey T, Su Z, Ogden RT. Generated effect modifiers (GEM’s) in randomized clinical trials. Biostatistics. 2017;18(1):105–18. 10.1093/biostatistics/kxw035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5255046</ArticleId><ArticleId IdType="pubmed">27465235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeng X, Lu W, Peng H. High-dimensional inference for personalized treatment decision. Electron J Stat. 2018;12:2074–89. 10.1214/18-EJS1439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6226259</ArticleId><ArticleId IdType="pubmed">30416643</ArticleId></ArticleIdList></Reference><Reference><Citation>Laber EB, Staicu A. Functional Feature Construction for Individualized Treatment Regimes. J Am Stat Assoc. 2018;113:1219–27. 10.1080/01621459.2017.1321545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6223315</ArticleId><ArticleId IdType="pubmed">30416232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Laber E, Ning Y, Saha S, Sands B. Efficient augmentation and relaxation learning for individualized treatment rules using observational data. J Mach Learn Res. 2019;20:1–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705615</ArticleId><ArticleId IdType="pubmed">31440118</ArticleId></ArticleIdList></Reference><Reference><Citation>Breiman L, Friedman JH. Predicting multivariate responses in multiple linear regression. J R Stat Soc Ser B Stat Methodol. 1997;59(1):3–54.</Citation></Reference><Reference><Citation>Gueorguieva RV, Agresti A. A correlated probit model for joint modeling of clustered binary and continuous responses. J Am Stat Assoc. 2001;96(455):1102–12. 10.1198/016214501753208762.</Citation></Reference><Reference><Citation>Rothman AJ, Levina E, Zhu J. Sparse multivariate regression with covariance estimation. J Comput Graph Stat. 2010;19(4):947–62. 10.1198/jcgs.2010.09188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4065863</ArticleId><ArticleId IdType="pubmed">24963268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai R, Ghosh M. High-dimensional multivariate posterior consistency under global-local shrinkage priors. J Multivar Anal. 2018;167:157–70. 10.1016/j.jmva.2018.04.010.</Citation></Reference><Reference><Citation>Bottolo L, Banterle M, Richardson S, Ala-Korpela M, Järvelin MR, Lewin A. A computationally efficient Bayesian seemingly unrelated regressions model for high-dimensional quantitative trait loci discovery. J R Stat Soc: Ser C: Appl Stat. 2021;70(4):886–908. 10.1111/rssc.12490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7612194</ArticleId><ArticleId IdType="pubmed">35001978</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu D, Mitra R, Gaskins JT. Bayesian variable selection for multioutcome models through shared shrinkage. Scand J Stat. 2021;48(1):295–320. 10.1111/sjos.12455.</Citation></Reference><Reference><Citation>Li X, Ghosh J, Villarini G. A comparison of Bayesian multivariate versus univariate normal regression models for prediction. Am Stat. 2022;p. 1–9. 10.1080/00031305.2022.2087735.</Citation></Reference><Reference><Citation>Agresti A, Natarajan R. Modeling clustered ordered categorical data: a survey. Int Stat Rev. 2001;69(3):345–71. 10.1111/j.1751-5823.2001.tb00463.x.</Citation></Reference><Reference><Citation>Qiu Z, Song PXK, Tan M. Bayesian hierarchical models for multi-level repeated ordinal data using WinBUGS. J Biopharm Stat. 2002;12(2):121–35. 10.1081/bip-120014415.</Citation><ArticleIdList><ArticleId IdType="pubmed">12413235</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansourian M, Kazemnejad A, Kazemi I, Zayeri F, Soheilian M. Bayesian analysis of longitudinal ordered data with flexible random effects using McMC: application to diabetic macular Edema data. J Appl Stat. 2012;39(5):1087–100. 10.1080/02664763.2011.638367.</Citation></Reference><Reference><Citation>Kang T, Gaskins J, Levy S, Datta S. Analyzing dental fluorosis data using a novel Bayesian model for clustered longitudinal ordinal outcomes with an inflated category. Stat Med. 2022;42(6):745–60. 10.1002/sim.9641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11180454</ArticleId><ArticleId IdType="pubmed">36574753</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H, Tarpey T, Liu Mea. Development and validation of a treatment benefit index to identify hospitalized patients with COVID-19 who may benefit from convalescent plasma. JAMA Netw Open. 2022;5(1):e2147375. 10.1001/jamanetworkopen.2021.47375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790670</ArticleId><ArticleId IdType="pubmed">35076698</ArticleId></ArticleIdList></Reference><Reference><Citation>Thas O, Neve JD, Clement L, Ottoy JP. Probabilistic index models. J R Stat Soc Ser B Stat Methodol. 2012;74(4):623–71. 10.1111/j.1467-9868.2011.01020.x.</Citation></Reference><Reference><Citation>Laber EB, Wu F, Munera C, Lipkovich I, Colucci S, Ripa S. Identifying Optimal Dosage Regimes Under Safety Constraints: An Application to Long Term Opioid Treatment of Chronic Pain. Stat Med. 2018;37:1407. 10.1002/SIM.7566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6293986</ArticleId><ArticleId IdType="pubmed">29468702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizotte DJ, Bowling MH, Murphy SA. Efficient reinforcement learning with multiple reward functions for randomized controlled trial analysis. In: ICML 2010 - Proceedings, 27th International Conference on Machine Learning. 2010:695–702.</Citation></Reference><Reference><Citation>Laber EB, Lizotte DJ, Ferguson B. Set-valued dynamic treatment regimes for competing outcomes. Biometrics. 2014;70:53–61. 10.1111/biom.12132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3954452</ArticleId><ArticleId IdType="pubmed">24400912</ArticleId></ArticleIdList></Reference><Reference><Citation>Laber EB, Lizotte DJ. Multi-Objective Markov Decision Processes for Data-Driven Decision Support. J Mach Learn Res. 2016;17:1–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5179144</ArticleId><ArticleId IdType="pubmed">28018133</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Fu H, Zeng D. Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. 2018;113:1–13. 10.1080/01621459.2017.1303386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051551</ArticleId><ArticleId IdType="pubmed">30034060</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler EL, Laber EB, Davis SM, Kosorok MR. Incorporating Patient Preferences into Estimation of Optimal Individualized Treatment Rules. Biometrics. 2018;74:18–26. 10.1111/BIOM.12743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5785589</ArticleId><ArticleId IdType="pubmed">28742260</ArticleId></ArticleIdList></Reference><Reference><Citation>Siriwardhana C, Datta S, Kulasekera KB. Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures. J Biopharm Stat. 2020;30:462–80. 10.1080/10543406.2019.1684304.</Citation><ArticleIdList><ArticleId IdType="pubmed">31691633</ArticleId></ArticleIdList></Reference><Reference><Citation>Luckett DJ, Laber EB, Kim S, Kosorok MR. Estimation and Optimization of Composite Outcomes. J Mach Learn Res. 2021;22:167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562677</ArticleId><ArticleId IdType="pubmed">34733120</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Zeng D, Wang Y. Learning Individualized Treatment Rules for Multiple-Domain Latent Outcomes. J Am Stat Assoc. 2021;116:269–82. 10.1080/01621459.2020.1817751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589272</ArticleId><ArticleId IdType="pubmed">34776561</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkeser D, Mertens A, Colford JM, Hubbard A, Arnold BF, Stein A, et al. A machine learning-based approach for estimating and testing associations with multivariate outcomes. Int J Biostat. 2021;17:7–21. 10.1515/ijb-2019-0061.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulasekera KB, Siriwardhana C. Quantiles based personalized treatment selection for multivariate outcomes and multiple treatments. Stat Med. 2022;41:2695–710. 10.1002/SIM.9377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9232994</ArticleId><ArticleId IdType="pubmed">35699385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizotte DJ, Bowling M, Murphy SA. Linear fitted-q iteration with multiple reward functions. J Mach Learn Res. 2012;13(1):3253–95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3670261</ArticleId><ArticleId IdType="pubmed">23741197</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldfeld KS, Wu D, Tarpey T, Liu M, Wu Y, Troxel AB, et al. Prospective individual patient data meta-analysis: evaluating convalescent plasma for COVID-19. Stat Med. 2021;40(24):5131–51. 10.1002/sim.9115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8441650</ArticleId><ArticleId IdType="pubmed">34164838</ArticleId></ArticleIdList></Reference><Reference><Citation>Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw Open. 2022;5(1):e2147331. 10.1001/jamanetworkopen.2021.47331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8790669</ArticleId><ArticleId IdType="pubmed">35076699</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Goldfeld KS, Petkvoa E. Developing a Bayesian hierarchical model for a prospective individual patient data meta-analysis with continuous monitoring. BMC Med Res Methodol. 2023. 10.1186/s12874-022-01813-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9875783</ArticleId><ArticleId IdType="pubmed">36698073</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–7. 10.1016/S1473-3099(20)30483-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A. Categorical data analysis. John Wiley &amp; Sons; 2002.</Citation></Reference><Reference><Citation>Stan Development Team. Stan modeling language users guide. 2020. https://mc-stan.org/docs.</Citation></Reference><Reference><Citation>Goldfeld KS, Wujciak-Jens J. Package “simstudy” R topics documented. 2020. https://cran.r-project.org/web/packages/simstudy/simstudy.pdf.</Citation></Reference><Reference><Citation>Fawcett T. An introduction to ROC analysis. Pattern Recogn Lett. 2006;27(8):861–74.</Citation></Reference><Reference><Citation>Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 2011;12(1):1–8. 10.1186/1471-2105-12-77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. https://covid19.who.int. Accessed 18 July 2024.</Citation></Reference><Reference><Citation>Donald RB. Bayesianly justifiable and relevant frequency calculations for the applied statistician. Ann Stat. 1984;12(4):1151–72. 10.1214/aos/1176346785.</Citation></Reference><Reference><Citation>Gelman A, Meng XL, Stern H. Posterior predictive assessment of model fitness via realized discrepancies. Stat Sin. 1996;6(4):733–807.</Citation></Reference><Reference><Citation>Gabry J, Simpson D, Vehtari A, Betancourt M, Gelman A. Visualization in Bayesian workflow. J R Stat Soc Ser A Stat Soc. 2019;182(2):389–402. 10.1111/rssa.12378.</Citation></Reference><Reference><Citation>Betancourt M. A conceptual introduction to Hamiltonian Monte Carlo. 2018. 10.48550/arXiv.1701.02434.</Citation></Reference><Reference><Citation>Betancourt M. Diagnosing suboptimal cotangent disintegrations in Hamiltonian Monte Carlo. 2016. 10.48550/arXiv.1604.00695.</Citation></Reference><Reference><Citation>Klami A, Virtanen S, Kaski S. Bayesian Canonical correlation analysis. J Mach Learn Res. 2013;14(30):965–1003. http://jmlr.org/papers/v14/klami13a.html.</Citation></Reference><Reference><Citation>Ferreira FS, Mihalik A, Adams RA, Ashburner J, Mourao-Miranda J. A hierarchical Bayesian model to find brain-behaviour associations in incomplete data sets. NeuroImage. 2022;249:118854. 10.1016/j.neuroimage.2021.118854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8861855</ArticleId><ArticleId IdType="pubmed">34971767</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TJ, Beauchamp JJ. Bayesian variable selection in linear regression. J Am Stat Assoc. 1988;83(404):1023–32.</Citation></Reference><Reference><Citation>Park T, Casella G. The Bayesian Lasso. J Am Stat Assoc. 2008;103(482):681–6. 10.1198/016214508000000337.</Citation></Reference><Reference><Citation>O’Hara RB, Sillanpää MJ. A review of Bayesian variable selection methods: what, how and which. Bayesian Anal. 2009;4(1):85–117. 10.1214/09-BA403.</Citation></Reference><Reference><Citation>Carvalho CM, Polson NG, Scott JG. The horseshoe estimator for sparse signals. Biometrika. 2010;97(2):465–80. 10.1093/biomet/asq017.</Citation></Reference><Reference><Citation>Van Erp S, Oberski DL, Mulder J. Shrinkage priors for Bayesian penalized regression. J Math Psychol. 2019;89:31–50. 10.1016/j.jmp.2018.12.004.</Citation></Reference><Reference><Citation>Murphy SA, Oslin DW, Rush AJ, Zhu J. Methodological challenges in constructing effective treatment sequences for chronic psychiatric disorders. Neuropsychopharmacology. 2007;32(2):257–62. 10.1038/sj.npp.1301241.</Citation><ArticleIdList><ArticleId IdType="pubmed">17091129</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Rotnitzky A, Lin X, Millikan RE, Thall PF. Evaluation of viable dynamic treatment regimes in a sequentially randomized trial of advanced prostate cancer. J Am Stat Assoc. 2012;107(498):493–508. 10.1080/01621459.2011.641416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3433243</ArticleId><ArticleId IdType="pubmed">22956855</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Tsiatis AA, Laber EB, Davidian M. Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions. Biometrika. 2013;100(3):681–94. 10.1093/biomet/ast014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843953</ArticleId><ArticleId IdType="pubmed">24302771</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Choi S, Wang L, Thall PF. Optimization of multi-stage dynamic treatment regimes utilizing accumulated data. Stat Med. 2015;34(26):3424–43. 10.1002/sim.6558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4596799</ArticleId><ArticleId IdType="pubmed">26095711</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray TA, Yuan Y, Thall PF. A Bayesian machine learning approach for optimizing dynamic treatment regimes. J Am Stat Assoc. 2018;113(523):1255–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6366650</ArticleId><ArticleId IdType="pubmed">30739965</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SA. Optimal dynamic treatment regimes. J R Stat Soc Ser B Stat Methodol. 2003;65(2):331–55. 10.1111/1467-9868.00389.</Citation></Reference><Reference><Citation>Robins JM. Optimal structural nested models for optimal sequential decisions. In: Proceedings of the Second Seattle Symposium in Biostatistics: analysis of Correlated Data. Springer; 2004. pp. 189–326.</Citation></Reference><Reference><Citation>Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, part I: main content. Int J Biostat. 2010;6(2):8. 10.2202/1557-4679.1200.</Citation><ArticleIdList><ArticleId IdType="pubmed">21969994</ArticleId></ArticleIdList></Reference><Reference><Citation>Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part II: proofs of results. Int J Biostat. 2010;6(2). 10.2202/1557-4679.1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854089</ArticleId><ArticleId IdType="pubmed">20405047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zajonc T. Bayesian inference for dynamic treatment regimes: Mobility, equity, and efficiency in student tracking. J Am Stat Assoc. 2012;107(497):80–92. 10.1080/01621459.2011.643747.</Citation></Reference><Reference><Citation>Vansteelandt S, Joffe M. Structural nested models and G-estimation: the partially realized promise. Stat Sci. 2014;29(4). 10.1214/14-sts493.</Citation></Reference><Reference><Citation>Moodie EE, Dean N, Sun YR. Q-learning: Flexible learning about useful utilities. Stat Biosci. 2014;6:223–43. 10.1007/s12561-013-9103-z.</Citation></Reference><Reference><Citation>Saarela O, Arjas E, Stephens DA, Moodie EE. Predictive Bayesian inference and dynamic treatment regimes. Biom J. 2015;57(6):941–58. 10.1002/bimj.201400153.</Citation><ArticleIdList><ArticleId IdType="pubmed">26259996</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Müller P, Wahed AS, Thall PF. Bayesian nonparametric estimation for dynamic treatment regimes with sequential transition times. J Am Stat Assoc. 2016;111(515):921–50. 10.1080/01621459.2015.1086353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5175473</ArticleId><ArticleId IdType="pubmed">28018015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Zhang M. C-learning: a new classification framework to estimate optimal dynamic treatment regimes. Biometrics. 2018;74(3):891–9. 10.1111/biom.12836.</Citation><ArticleIdList><ArticleId IdType="pubmed">29228509</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Laber EB, Davidian M, Tsiatis AA. Interpretable dynamic treatment regimes. J Am Stat Assoc. 2018;113(524):1541–9. 10.1080/01621459.2017.1345743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6373443</ArticleId><ArticleId IdType="pubmed">30774169</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SA, van der Laan MJ, Robins JM, Group CPPR. Marginal mean models for dynamic regimes. J Am Stat Assoc. 2001;96(456):1410–23. 10.1198/016214501753382354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794446</ArticleId><ArticleId IdType="pubmed">20019887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>